A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Inclusion Criteria:

• Subjects with histologically or cytologically confirmed history of IDH-wild typeglioblastoma

• Phase 1b and Arm B of Phase 2: Subjects must have completed no more than onestandard therapy for glioblastoma, have received no prior Avastin® therapy (unless solely used for edema management) and be eligible for resection

• Arms A and C: Subjects must have newly diagnosed, treatment naïve glioblastoma

• Phase 1b and Arm B and Arm C: Subjects must have a partially matchedhaploidentical or matched related donor.

• Subjects with magnetic resonance imaging (MRI) features consistent with andsuspicious for recurrent malignant glioma in Phase 1b and Arm B.

• Agreeable to inserting and maintaining a Rickham catheter.

• ≥ 18 years of age.

• Karnofsky Performance Status ≥ 70%

• Female subjects of childbearing potential must have a negative urine/serum pregnancytest within 72 hours of study enrollment. Female subjects of childbearing potentialare those who have not been surgically sterilized or have not been free of mensesfor > 2 years.

• Male subjects and their female partners and female subjects of childbearingpotential must be willing to use a combination of two methods of birth control or besurgically sterile or abstain from heterosexual activity for the course of thestudy.

Exclusion Criteria:

• Subject in Arm A or donor from Phase 1b, Arms B, and Arm C received vaccinationswithin 4 weeks or underwent surgery (major or minor) within 72 hours beforeleukapheresis collection.

• Cellular immunotherapy or gene therapy or within six weeks prior to entering thestudy, surgical resection or alkylating agent chemotherapy within four weeks priorto entering the study, receiving tumor treating fields (TTF) Optune therapy, or havereceived experimental immunotherapy at any time

• Subjects receiving any other investigational agents concurrently while on study.

• Have not recovered from adverse events (≤ Grade 1) from previously administeredtherapy. Subjects with alopecia unless of immune origin are an exception to thiscriterion and may qualify for this study

• Have received prior treatment with an allogeneic therapy, including bone marrow orsolid tumor transplant.

• Concurrent malignancy or an active second malignancy. Subjects with a history ofsecond malignancy must have no evidence of cancer for two years prior to enrolmentor have a surgically cured cancer with low risk of recurrence to enroll. Discusswith medical monitor prior to enrolment.

• Contraindication to the placement of an intracranial access device (Rickhamcatheter) at the time of surgery.

• Prior history of encephalitis, multiple sclerosis, or other CNS infection <1 yearprior to glioblastoma diagnosis.

• Uncontrolled intercurrent illness including, but not limited to ongoing or activeinfection, or any other medical condition that precludes surgery. Also,medical/surgical/psychiatric illness/social situations that would limit compliancewith study requirements or confound interpretation of safety and efficacy data.Subjects with a history of seizure as a result of their glioblastoma must be seizurefree and on appropriate anti-epileptic medication for 3 weeks prior to dosing withthe investigational agent.

• Allergies/hypersensitivity to amino bisphosphonates such as Zoledronate®,Pamidronate® or similar.

• History of HIV or active hepatitis even if well controlled or history of anautoimmune condition.